Pediatric study for a combination product [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-02-20 20:59 (2309 d 19:03 ago) – Posting: # 21185
Views: 3,668
(edited on 2020-02-20 23:12)

Hi,

Question:
For the development of a fixed dose combination (FDC) product containing two ingredient, is there a need to do pediatric PK study
  1. if the individual references' dosages are applicable to adolescent 12 and up and adult? ie: FDC contains 10 mg A and 20 mg B. A @ 10 mg and B @ 20 mg can be taken by 12 yrs old. And there is no drug drug interaction.
  2. if the new FDC has a new dosing interval that is different from both references?

Thx
J

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
164 visitors (0 registered, 164 guests [including 20 identified bots]).
Forum time: 17:03 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5